Iverscab

Ivermectin, the active ingredient in Iverscab, is an antiparasitic (anthelmintic) presented as a tablet for oral use. It treats a range of helminthic and ectoparasitic infections in both adults and children.

GNH USA supplies Iverscab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectin is used to treat parasitic diseases by targeting the organisms responsible for infection.

- Strongyloidiasis: eliminates intestinal Strongyloides stercoralis, reducing chronic infection and preventing hyperinfection. - Onchocerciasis: kills Onchocerca volvulus microfilariae, helping control river blindness. - Scabies: eradicates Sarcoptes scabiei mites, relieving skin infestation. - Lymphatic filariasis: reduces Wuchereria bancrofti adult worms, aiding in disease control. - Other parasitic infections: provides broad‑spectrum activity against various nematodes and ectoparasites.

Ivermectin may cause adverse reactions ranging from mild to severe.

Common Side Effects: - Nausea: mild stomach upset often transient. - Dizziness: occasional light‑headedness. - Diarrhea: loose stools during treatment. - Headache: mild to moderate pain.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Neurologic effects: seizures, ataxia or altered consciousness.

When prescribing Iverscab, clinicians should consider the following precautions.

- Liver function: assess hepatic status before initiating therapy. - Hypersensitivity: avoid in patients with known allergy to ivermectin or excipients. - Concomitant CNS depressants: use with caution as additive neuro‑depressive effects may occur. - Pregnancy and lactation: evaluate risk‑benefit; limited data available. - Drug interactions: review concurrent medications for potential interactions. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Ivermectin can interact with other medicines; notable interactions include:

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase ivermectin plasma levels. - P‑glycoprotein inhibitors (e.g., verapamil, quinidine): can raise systemic exposure. - Co‑administration with other neurotoxic anthelmintics: risk of additive neurotoxicity.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation. - Statins (e.g., simvastatin): may raise risk of myopathy. - Macrolide antibiotics (e.g., erythromycin): moderate CYP3A4 inhibition, observe for enhanced effects.